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Prognostic value of loss of heterozygosity at BRCA2 in
human breast carcinoma
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Summary To confirm several recent studies pointing to loss of heterozygosity (LOH) at BRCA2 as a prognostic factor in sporadic breast
cancer, we examined this genetic alteration in a large series of human primary breast tumours for which long-term patient outcomes were
known. LOH at BRCA2correlated only with low oestrogen and progesterone receptor content. Univariate analysis of metastasis-free survival
and overall survival (log-rank test) showed no link with BRCA2 status (P = 0.34, P = 0.29 respectively). LOH at BRCA2 does not therefore
appear to be a major prognostic marker in sporadic breast cancer.
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Breast cancer, one ofthe mostcommon life-threatening diseases in
women, occurs in hereditary and sporadic forms. The two major
breast cancer susceptibility genes, BRCAI and BRCA2, were
recently isolated (Miki et al, 1994; Wooster et al, 1995; Couch et
al, 1996). Both are considered to be tumour-suppressor genes and
are thought to be inactivated by a 'two-hit' mechanism originally
proposed by Knudson to explain the tumorigenesis ofretinoblast-
oma. In hereditary cancer, the first hit would be a germline muta-
tion in a specific cancer gene, whereas in sporadic cancer the first
hit would be a somatic mutation or another inactivating molecular
event. The second hit would be a loss of the second gene copy in
the somatic cell, in both hereditary and sporadic forms. A number
ofgermline mutations in the BRCAJ and BRCA2 genes have been
identified in families prone tobreast cancer (Shattuck-Eidens etal,
1995; Couch et al, 1996, Phelan et al, 1996). In sporadic forms,
somatic BRCA2 mutations, like somatic mutations in the BRCAJ
gene, are rare (Lancaster et al, 1996; Miki et al, 1996; Teng et al,
1996). However, aberrant subcellular location (Chen et al, 1995)
and reduced expression of BRCAJ (Thompson et al, 1995),
together with high frequencies ofloss ofheterozygosity (LOH) on
17ql2-q21 and 13ql2-ql3 (sites ofBRCAI and BRCA2) (Bieche
and Lidereau, 1995), point to a significant role ofthese two genes
in thetumorigenesis ofsporadic breast cancer, butthrough amech-
anism other than structural mutation. LOH on 13ql2-ql3 occurs
in 30-60% of somatic breast tumours (Cleton-Jansen et al, 1995;
Kerangueven et al, 1995; Beckmann et al, 1996; Hamann et al,
1996; Kelsell et al, 1996). These LOH studies identified a
consensus region of deletion involving BRCA2 and excluding the
RB1 locus. Several studies have pointed to a link between BRCA2
inactivation (mutation and/or LOH) and Scarff, Bloom and
Richardson (SBR) histopathological grade 3, in both hereditary
and sporadic forms ofbreast cancer, suggesting the involvement of
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this gene in the aggressiveness of breast tumours (Bignon et al,
1995; Beckmann et al, 1996; Kelsell et al, 1996). Recently, in a
pilot study, LOH at BRCA2 was found to be an independent prog-
nostic factor (van den Berg et al, 1996). However, this study
involved a heterogeneous population of 84 primary tumours from
both familial (n = 45) and sporadic (n = 39) cases ofbreast cancer.
To confirm this pilot study, we examined a larger series of
human primary sporadic breast tumours (n = 102) with longer
follow-up.
We reviewed excised primary breast tumours from 102 women
treated at the Centre Rene Huguenin from 1977 to 1989. These
patients (mean age 57 years; range 34-86) met the following
criteria: primary unilateral invasive breast carcinoma; no other
primary cancer or metastasis (supraclavicular nodes included); no
radiotherapy or chemotherapy before surgery; and complete clin-
ical, histological and biological data. According to the 1979 UICC
criteria, 11 women were in stage I, 70 in stage II, 19 in stage Illa
and two in stage IlIb. The main tumour characteristics are
presented in Table 1. Oestrogen and progesterone receptor assays
were performed using the method described by the European
Organization for Research and Treatment for Cancer (EORTC,
1980), with a detection limit of 10 fmol mg-' cytosolic protein.
Eighty (78.4%) tumours were infiltrating ductal carcinomas. All
the patients underwent a physical examination and routine chest
radiography every 3 months for the first 2 years and annually
thereafter. Liver scintigraphy, bone scans and mammograms were
performed annually. The median follow-up was 9 years (range
1.4-16.2). The cut-offdate for the analysis was January 1996. All
but two ofthe 27 deaths were related to breast cancer; 37 patients
relapsed (eight local and/or regional recurrences, 22 metastases,
three both and four contralateral breast tumours). Two second
invasive cancers occurred. Overall survival (S) was based on the
time from diagnosis to breast cancer-related death; metastasis-free
survival (MFS) on the time from diagnosis to detection ofthe first
metastasis or to breast cancer death without apparent metastasis.
The univariate analysis ofMFS (log-rank test) is reported in Table
1; lymph node status was the only classical explanatory variable
associated with MFS.
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Table 1 Characteristics of the 102 patients and relation to metastasis-free
survival
Metastasis-free survival
Number of Number of Five-year P.valued
patients (%) eventsa rateb (s.e.)c
Menopausal status NS
Premenopausal 42 (41.2) 15 83.3 (5.7)
Post-menopausal 60 (58.8) 21 84.4 (4.8)
Histological gradee NS
11(11.6) 3 100
11 49 (51.6) 20 77.0 (6.1)
III 35 (36.8) 13 85.0 (6.2)
Lymph node status 0.022
Node-negative 33 (32.4) 5 84.5 (6.4)
Node-positive 69 (67.6) 31 83.7 (4.5)
ER status NS
+ (210fmol mg-1) 35 (34.3) 12 79.2 (7.0)
- (< 10 fmol mg-') 67 (65.7) 24 86.3 (4.2)
PR status NS
+ (2 10fmol mg-') 44 (43.1) 15 83.5 (5.7)
- (< 10 fmol mg-,) 58 (56.9) 21 84.2 (4.8)
Macroscopic tumour size NS
<30 mm 67 (69.1) 23 83.1 (4.6)
> 30 mm 30 (30.9) 11 82.9 (7.0)
aFirst metastasis, or breast cancer-related death without apparent
metastases; bKaplan-Meier estimate; cstandard error; dlog-rank test;
eScarff-Bloom-Richardson classification.
Table 2 Relationship between LOH at BRCA2and the standard
clinicopathological and biological factors
BRCA2LOH(%) P-values
Total 42.4
Histological gradeb NS
27.3
11 39.6
III 48.6
Mitotic index 0.017
18.2
11 25.0
III 52.5
Lymph node status NS
Node-negative 41.9
Node-positive 42.6
ER status 0.009
+ (2 10 fmol mg-,) 32.8
- (< 10 fmol mg-,) 60.0
PR status 0.050
+ (2 10 fmol mg-') 33.9
- (< 10 fmol mg-') 53.5
Macroscopic tumour size NS
<30 mm 39.4
> 30 mm 44.8
aChi-square test; bScarff-Bloom-Richardson classification.
Immediately following surgery the tumour samples were stored in
liquid nitrogen until extraction of high-molecular-weight DNA.
Patients were included in this study if the tumour sample used
for DNA preparation contained more than 60% of tumour cells by
histological analysis. A blood sample was also taken from
each patient. DNA was extracted from frozen tumour tissue and
blood leucocytes of each patient using standard methods (Maniatis
etal, 1982).
The carcinomas were screened with three polymorphic
microsatellite DNA marker loci flanking BRCA2 (D13S260,
D13S171, D13S267) to identify the maximum number ofpatients
informative for at least one locus.
PCR was run in a total volume of 50 gl, with 50 ng ofgenomic
DNA, 20 mm ofeach primer, 1.5 mm magnesium chloride, 0.1 mm
of each deoxynucleotide triphosphate and one unit of Taq DNA
polymerase. Microsatellite markers were assayed by PCR amplifi-
cation of genomic DNA. The annealing temperature, number of
amplification cycles and extension time were adapted to each
primer set. One microlitre ofproduct was mixed with 3 ,ul ofdena-
turing loading buffer and heat denatured, then 1.5-gl aliquots of
each sample were loaded on 6% acrylamide gels containing 7.5 M
urea. DNA was then transferred to nylon membrane filters. The
CA repeat probe was labelled with [32P]dCTP using terminal
deoxynucleotidyl transferase. The membrane filters were
hybridized overnight at 42°C with the labelled probe, washed and
autoradiographed at-80°C for an appropriate period.
Normal DNA samples that were polymorphic at a given locus
were considered to be 'informative', whereas homozygotes were
considered 'uninformative'. Only cases of constitutional hetero-
zygosity were used in the evaluation ofLOH. The signal intensity
of the polymorphic alleles was determined by visual examination
(three observers) and confirmed by means of densitometry. The
results of all the scanned samples were in direct agreement with
the initial visual scoring. LOH was considered to occur when the
intensity ofthe allele in tumour DNA was less than 40% ofthat in
corresponding normal tissue DNA (peripheral blood lympho-
cytes). LOH was partial, in most cases the band being fainter than
the conserved allele but still visible. Such partial losses are due
either to contaminating normal tissue or to tumourheterogeneity.
LOH at BRCA2 was found in 42.4% of 99 informative
(heterozygous) tumour DNAs. Table 2 gives detailed results ofthe
correlations between LOH at BRCA2 and the standard prognostic
parameters including macroscopic tumour size, histological grade
and lymph node or steroid receptor status. No link between
BRCA2 status (LOH vs normal) and macroscopic tumour size or
lymph node status was found (%2 analysis). Oestrogen and proges-
terone receptor negativity were both associated with a higher
percentage of LOH at BRCA2 (P = 0.009, P = 0.05 respectively),
in agreement with van den Berg et al (1996). Although no link
was found between the percentage of LOH at BRCA2 and
Scarff-Bloom-Richardson (SBR) histopathological grade (P =
0.42), there was a correlation with the mitotic index, which is one
of the three components of the SBR classification (P = 0.017).
This was in partial agreement with previous reports of a link
between LOH at BRCA2 and SBR histopathological grade III
(Beckmann et al, 1996; Kelsell et al, 1996). Univariate analysis of
MFS and S (log-rank test) showed no link with BRCA2 status
(P = 0.34, P = 0.29 respectively). Even if the metastasis-free
survival of 42 patients with LOH at BRCA2 was slightly shorter
than that of 57 patients without LOH [5-year MFS 75.7% (s.e. =
6.7%) vs 89.2% (s.e. = 4.2%)], this was not the case of overall
survival [5-year S 92.7% (s.e. = 4.1%) vs 91.0% (s.e. = 3.9%)].
Our results do not support the notion that inactivation of a
tumour-suppressor gene located at 13ql2-ql3 (BRCA2 or another
gene) is a majorprognostic marker in breast cancer.
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